{"url_path":"/sec/elox/8-k/2026-06-01/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-01","source_url":"https://www.sec.gov/Archives/edgar/data/1035354/0001193125-26-249692-index.html","accession_number":"0001193125-26-249692","cik":"0001035354","ticker":"ELOX","issuer_name":"Eloxx Pharmaceuticals, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1035354/0001193125-26-249692-index.html","primary_entity_key":"0001035354","primary_entity_name":"Eloxx Pharmaceuticals, Inc."},"word_count":89,"has_tables":true,"body_markdown":"Item 9.01.\n\nFinancial Statements and Exhibits.\n\n(d) Exhibits\n\n \n\nExhibit\nNumber\n\n  \n\nExhibit Description\n\n3.1\n  \n[Certificate of Amendment to the Amended and Restated Certificate of Incorporation of the Registrant.](d261568dex31.htm)\n\n104\n  \nCover Page Interactive Data File (embedded within Inline XBRL document).\n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\nDate: June 1, 2026\n \n\n \nELOXX PHARMACEUTICALS, INC.\n\n \n\n \nBy:\n \n\n/s/ Sumit Aggarwal\n\n \n\n \nName:\n \nSumit Aggarwal\n\n \n\n \nTitle:\n \nPresident and Chief Executive Officer"}